Polymyalgia rheumatica is widely acknowledged as the most common form of inflammatory rheumatic disease in the elderly. Two recent studies by Hernandez-Rodriguez et al. and Dasgupta et al. attempt to synthesize and pragmatize recommendations for the evaluation and treatment of this disorder.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gonzalez-Gay, M. A. et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a ten-year study. J. Rheumatol. 26, 1326–1332 (1999).
Kyle, V. & Hazleman, B. L. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dosing and steroid associated side effects. Ann. Rheum. Dis. 48, 662–666 (1989).
Hernandez-Rodriguez, J., Cid, M. C., Lopez-Soto, A., Espigol-Frigole, G. & Bosch, X. Treatment of polymyalgia rheumatica: a systematic review. Arch. Intern. Med. 169, 1839–1850 (2009).
Dasgupta, B. et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49, 186–190 (2010).
Dasgupta, B. et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J. Rheumatol. 35, 270–277 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Matteson, E. Unraveling the tautology of polymyalgia rheumatica. Nat Rev Rheumatol 6, 249–250 (2010). https://doi.org/10.1038/nrrheum.2010.40
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.40
